Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY
Milestone Scientific (NYSE: MLSS) reported preliminary, unaudited revenue for Q2 2026 of about $2.8M (+21% YoY) and 1H 2026 of about $5.0M (+9% YoY). The company expects medical-segment revenue up 300% YoY in Q2 and cites international order upside, plus reimbursement claims and conference plans in July.
How this was made
The 30-second read
Why it matters
The company ties revenue growth to international orders, a surge in medical-segment growth (300% YoY in Q2), and reimbursement progress (100 claims submitted; first paid workers’ compensation claim). It also flags upcoming technology showcase at an ASPN conference (July 16-18) and plans to release full results in August.
Market read
Fresh preliminary revenue numbers plus specific commercialization/reimbursement milestones can drive near-term positioning ahead of the August full financial release.
What to watch
Medical segment is still “growing from a small base,” so percentage growth may not translate into material earnings power; dental expansion approvals may take time to monetize.
Background
Milestone Scientific is a computerized drug-delivery instruments company; this is a preliminary, unaudited revenue update for Q2 and 1H 2026.
Ticker impact
Milestone Scientific (MLSS) reports preliminary Q2’26 revenue of ~$2.8M (+21% YoY) and 1H’26 revenue of ~$5.0M (+9% YoY).
Near-term upside bias versus prior expectations, with volatility risk until audited results in August.
The release provides fresh, time-sensitive revenue datapoints and specific business drivers (international orders, medical segment growth, reimbursement claims), though it is explicitly preliminary/unaudited.
Market effects
Adds incremental signal of demand and commercialization progress in computerized injection/drug-delivery instrumentation, potentially supporting sentiment for small-cap medtech peers.
International order upside cited could modestly improve outlook for revenue mix beyond the US.
Limited direct global read-through; mainly company-specific commercialization and reimbursement progress.
Counterpoint
Because figures are preliminary and unaudited, the market may discount them and focus on whether reimbursement progress converts into sustained revenue in later quarters.
Key entities
- companyMilestone Scientific Inc.
NYSE-listed medical/dental injection technology developer providing preliminary Q2’26 and 1H’26 revenue estimates.
- executiveEric Hines
CEO who attributed growth to international orders and medical-segment momentum plus reimbursement progress.
- board_memberDr. Dawood Sayed
Vice Chairman and co-founder of ASPN, quoted regarding the conference theme.
